Wei Liu1, Yue Zhang1, Shi Wei2, Sejong Bae3, Wei-Hsiung Yang4, Gary J Smith5, James L Mohler5, Elizabeth T H Fontham6, Jeannette T Bensen7, Guru P Sonpavde8, Guo-Yun Chen9, Runhua Liu1, Lizhong Wang1. 1. Department of Genetics and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama. 3. Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 4. Department of Biomedical Sciences, Mercer University, Savannah, Georgia. 5. Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York. 6. School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana. 7. Lineberger Comprehensive Cancer Center and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 8. Dana-Farber Cancer Institute, Boston, Massachusetts. 9. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee.
Abstract
BACKGROUND: Using a functional analysis of prostate cancer cells, we found a CD24-dependent inactivation of mutant p53, but the clinical significance of this observation remained uncertain. Here, we validated these results with samples of human prostate cancer and explored the role of a CD24-p53 axis in racial disparities of prostate cancer. METHODS: Samples of formalin-fixed, paraffin-embedded prostate cancer from 141 European Americans (EAs) and 147 African Americans (AAs) in two independent sample cohorts were assessed for protein expression of CD24, mutant p53, mouse double minute 2 human homolog (MDM2), and cyclin dependent kinase inhibitor 2A (ARF) using immunohistochemical analyses. All samples were analyzed for TP53R175H and TP53R273H . RESULTS: CD24, mutant p53, MDM2, and ARF proteins were expressed in 55%, 24%, 39%, and 68% of prostate cancer samples, respectively. CD24 and mutant p53 were present more frequently in late-stage and metastatic prostate cancer. The presence of CD24 was associated with a greater than fourfold risk of metastasis, which included lymph node and distant metastases. H score analysis showed positive correlations of CD24 expression with mutant p53 (r = .308, P < .001) and MDM2 (r = .227, P = .004). There was a negative correlation for CD24 with ARF (r = -.280, P < .001). A racial disparity was evident for CD24 (AAs/EAs: 64% vs 47%; P = .004) but not for mutant p53 (AA/EA: 28% vs 21%; P = .152). In 32 CD24+ /mutant p53+ cases, a TP53R273H mutation was found in five cases, but no TP53R175H mutation was found. CONCLUSION: The CD24-p53 axis may contribute to aggressive and metastatic prostate cancers, especially those of AAs. This observation enhances understanding of the pathogenesis of prostate cancer and its associated racial disparities.
BACKGROUND: Using a functional analysis of prostate cancer cells, we found a CD24-dependent inactivation of mutant p53, but the clinical significance of this observation remained uncertain. Here, we validated these results with samples of human prostate cancer and explored the role of a CD24-p53 axis in racial disparities of prostate cancer. METHODS: Samples of formalin-fixed, paraffin-embedded prostate cancer from 141 European Americans (EAs) and 147 African Americans (AAs) in two independent sample cohorts were assessed for protein expression of CD24, mutant p53, mouse double minute 2 human homolog (MDM2), and cyclin dependent kinase inhibitor 2A (ARF) using immunohistochemical analyses. All samples were analyzed for TP53R175H and TP53R273H . RESULTS:CD24, mutant p53, MDM2, and ARF proteins were expressed in 55%, 24%, 39%, and 68% of prostate cancer samples, respectively. CD24 and mutant p53 were present more frequently in late-stage and metastatic prostate cancer. The presence of CD24 was associated with a greater than fourfold risk of metastasis, which included lymph node and distant metastases. H score analysis showed positive correlations of CD24 expression with mutant p53 (r = .308, P < .001) and MDM2 (r = .227, P = .004). There was a negative correlation for CD24 with ARF (r = -.280, P < .001). A racial disparity was evident for CD24 (AAs/EAs: 64% vs 47%; P = .004) but not for mutant p53 (AA/EA: 28% vs 21%; P = .152). In 32 CD24+ /mutant p53+ cases, a TP53R273H mutation was found in five cases, but no TP53R175H mutation was found. CONCLUSION: The CD24-p53 axis may contribute to aggressive and metastatic prostate cancers, especially those of AAs. This observation enhances understanding of the pathogenesis of prostate cancer and its associated racial disparities.
Authors: Stephen A Brassell; Kevin R Rice; Patrick M Parker; Yongmei Chen; James S Farrell; Jennifer Cullen; David G McLeod Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Glen Kristiansen; Christian Pilarsky; Christoph Wissmann; Simone Kaiser; Thomas Bruemmendorf; Stefan Roepcke; Edgar Dahl; Bernd Hinzmann; Thomas Specht; Janja Pervan; Carsten Stephan; Stefan Loening; Manfred Dietel; André Rosenthal Journal: J Pathol Date: 2005-02 Impact factor: 7.996
Authors: Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-02-14 Impact factor: 508.702
Authors: Karla J Lindquist; Pamela L Paris; Thomas J Hoffmann; Niall J Cardin; Rémi Kazma; Joel A Mefford; Jeffrey P Simko; Vy Ngo; Yalei Chen; Albert M Levin; Dhananjay Chitale; Brian T Helfand; William J Catalona; Benjamin A Rybicki; John S Witte Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Yan Ping Yu; Douglas Landsittel; Ling Jing; Joel Nelson; Baoguo Ren; Lijun Liu; Courtney McDonald; Ryan Thomas; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich; Jian-Hua Luo Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Dinesh Singh; Phillip G Febbo; Kenneth Ross; Donald G Jackson; Judith Manola; Christine Ladd; Pablo Tamayo; Andrew A Renshaw; Anthony V D'Amico; Jerome P Richie; Eric S Lander; Massimo Loda; Philip W Kantoff; Todd R Golub; William R Sellers Journal: Cancer Cell Date: 2002-03 Impact factor: 31.743
Authors: Eduardo de Paula Nascente; Renée Laufer Amorim; Carlos Eduardo Fonseca-Alves; Veridiana Maria Brianezi Dignani de Moura Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575